Discovery of novel benzimidazole acyclic <i>C</i>‐nucleoside DNA intercalators halting breast cancer growth
作者:Mohamed N. Abd Al Moaty、Yeldez El Kilany、Laila Fathy Awad、Nihal Ahmed Ibrahim、Marwa M. Abu‐Serie、Amira El‐Yazbi、Mohamed Teleb
DOI:10.1002/ardp.202300454
日期:2024.1
selective derivatives against MCF-7 (half-maximal inhibitory concentration [IC50] = 0.060 and 0.080 µM, selectivity index [SI] = 9.68 and 8.27, respectively) and MDA-MB-231 cells (IC50 = 0.299 and 0.166 µM, SI = 1.94 and 3.98, respectively). Thus, they were identified as the study hits for mechanistic studies. Both derivatives induced DNA damage at 0.24 and 0.29 μM, respectively. The DNA damage kinetics
乳腺癌仍然是全世界最常见的癌症。在实践中,成功的临床结果是通过靶向 DNA 实现的。随着新型 DNA 靶向剂的引入取得进展,本文采用“糖方法”设计来开发带有与碳水化合物附属物相连的药效基序的新型嵌入剂。据此,合理设计、合成了新的苯并咪唑无环C核苷,并通过MTT(3-[4,5-二甲基噻唑-2-基]-2,5二苯基四唑溴化物)测定法评价其对MCF-7和MDA的细胞毒性。 -MB-231乳腺癌细胞与正常成纤维细胞(Wi-38)相比,与阿霉素相比。 ( 1S , 2R , 3S , 4R )-2-(1,2,3,4,5-五羟基)戊基-1H- 5,6-二氯苯并咪唑7和( 1S , 2R , 3S ,4 R )-2-(1,2,3,4,5-五羟基)戊基-1 H -萘噻咪唑13是针对 MCF-7 的最有效和选择性衍生物(半最大抑制浓度 [IC 50 ] = 0.060和 0.080 µM,选择性指数 [SI]